Singapore markets close in 4 hours 30 minutes

Boston Scientific Corporation (BSX.MX)

Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
1,394.230.00 (0.00%)
At close: 01:33PM CST
Full screen
Previous close1,394.23
Open1,394.23
Bid1,395.00 x N/A
Ask1,400.00 x N/A
Day's range0.00 - 0.00
52-week range
Volume2,742
Avg. volume400
Market cap2.05T
Beta (5Y monthly)0.79
PE ratio (TTM)64.10
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Boston Scientific Announces Conference Call Discussing Second Quarter 2024 Results

    Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on July 24 prior to the conference call.

  • GlobeNewswire

    Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific

    Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (“Silk Road”) (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (“Boston Scientific”) (NYSE: BSX), a global medical technology leader, for $27.50 in cash per share, representing an equity valu

  • PR Newswire

    Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc.

    Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The purchase price is $27.50 per share, reflecting an enterprise value of approximately $1.16 billion.i